Filtered By:
Condition: Thrombosis
Management: Economics
Countries: Netherlands Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
CONCLUSIONS: In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and potentially cost-saving alternative to VKA in the Netherlands.
PMID: 30614320 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 8, 2019 Category: Health Management Tags: J Med Econ Source Type: research
